Eli Lilly plans to launch experimental weight-loss pill in India
Sign up now: Get ST's newsletters delivered to your inbox
Eli Lilly's orforglipron is part of a new class of GLP-1 drugs that suppress appetite.
PHOTO: REUTERS
Follow topic:
MUMBAI – Pharmaceuticals manufacturer Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on Sept 25, offering an alternative to injectables that many patients in the world’s most populous nation resist.
Orforglipron is part of a new class of GLP-1 drugs that suppress appetite and follow the same pathway targeted by Eli Lilly’s blockbuster tirzepatide – sold globally as the blockbuster Mounjaro for diabetes and Zepbound for weight loss.
The drug has not been launched anywhere globally, but Eli Lilly plans to file for approval of orforglipron with regulators in the United States, Britain, European Union, Japan and China.
It was not immediately clear if the drugmaker has started approval procedure for orforglipron in India.
Latest trial data showed Eli Lilly’s orforglipron lowered blood sugar and weight more effectively than Novo Nordisk’s older GLP-1 drug Rybelsus in adults with Type 2 diabetes.
“There is promise for products like that in India, if it gets approved,” Mr Winselow Tucker, Eli Lilly India’s president, said, speaking at an industry conference panel in Mumbai. He did not give a launch timeline.
People in India would take their tablets rather than inject, said Novo Nordisk’s India head Vikrant Shrotriya.
Mr Tucker added that stigma and logistical hurdles also weigh on injectables.
Still, both companies remain upbeat on the market. Novo’s Wegovy and Eli Lilly’s Mounjaro, launched earlier in 2025, have seen a surge in demand, with sales doubling within months.
Mr Shrotriya said: “We are seeing growing acceptance of obesity injectables in India.” REUTERS
